Gumus Ilknur Inegol, Kaygusuz Ikbal, Derbent Aysel, Simavli Serap, Kafali Hasan
Department of Obstetrics and Gynecology, Fatih University School of Medicine, Ciftlik Cad. No: 57, 06510, Emek, Ankara, Turkey.
Int Urogynecol J. 2011 Jun;22(6):743-9. doi: 10.1007/s00192-011-1398-z. Epub 2011 Apr 2.
We evaluated the outcomes and the effect of the Macroplastique Implantation System on the quality of life in women with stress incontinence with or without a history of an anti-incontinence operation during 12 to 62 months follow-up.
Thirty-five women with urodynamically proven stress incontinence with intrinsic sphincter deficiency were included in this study. Macroplastique injection was performed in all patients. Quality of life was evaluated prior to therapy, in early postoperative time (at the sixth weeks) and in late postoperative time (12 to 62 months follow-up) with the use of three different questionnaires: Incontinence Quality-of-Life Questionnaire (I-QOL), Incontinence Impact Questionnaire-7 (IIQ-7), and Urogenital Distress Inventory-6 (UDI-6). Questionnaires were also compared with those previous to the anti-incontinence operation and to the primary procedure groups.
The median age of the women was 50.00 (interquartile range = 17.00) years. There were 24 primary procedures and 11 had undergone previous anti-incontinence surgery. Maximum follow-up time was 62 months, minimum follow-up time was 12 months, and the median follow-up time of the study was 58 (interquartile range = 44-60) months. When preoperative and postoperative median of the I-QOL, IIQ-7, and UDI-6 scores were compared, the differences between scores were found to be statistically significant. I-QOL, IIQ-7, and UDI-6 scores were related to the previous surgery. The overall I-QOL, IIQ-7, and UDI-6 summary scores showed high internal consistency.
The Macroplastique injection system is an effective, safe, and acceptable option for stress urinary incontinence in women with or without a history of an anti-incontinence operation. Moreover, it can be performed under local anesthesia without cystoscopic guidance; moreover, side effects are rare.
我们评估了Macroplastique植入系统在12至62个月随访期间，对有或无抗尿失禁手术史的压力性尿失禁女性的治疗效果及生活质量的影响。
本研究纳入了35名经尿动力学证实存在内在括约肌缺陷的压力性尿失禁女性。所有患者均接受了Macroplastique注射治疗。在治疗前、术后早期（第6周）和术后晚期（12至62个月随访）使用三种不同的问卷对生活质量进行评估：尿失禁生活质量问卷（I-QOL）、尿失禁影响问卷-7（IIQ-7）和泌尿生殖系统困扰量表-6（UDI-6）。问卷结果还与抗尿失禁手术前及初次手术组的结果进行了比较。
这些女性的中位年龄为50.00（四分位间距 = 17.00）岁。其中24例为初次手术，11例曾接受过抗尿失禁手术。最长随访时间为62个月，最短随访时间为12个月，研究的中位随访时间为58（四分位间距 = 44 - 60）个月。比较I-QOL、IIQ-7和UDI-6评分的术前和术后中位数时，发现评分差异具有统计学意义。I-QOL、IIQ-7和UDI-6评分与既往手术有关。I-QOL、IIQ-7和UDI-6的总体汇总评分显示出较高的内部一致性。
对于有或无抗尿失禁手术史的女性压力性尿失禁，Macroplastique注射系统是一种有效、安全且可接受的选择。此外，该操作可在局部麻醉下无需膀胱镜引导进行；而且副作用罕见。
